Previous 10 | Next 10 |
Verastem Now Focused on Development of VS-6766 and Defactinib Combination in Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer Registration-Directed Clinical Trials in LGSOC and KRAS Mutant NSCLC Expected to Commence by Year End 2020 Verastem...
Verastem (NASDAQ: VSTM ) is down 3% premarket on increased volume in reaction to updated results from a Phase 1/2 clinical trial, FRAME , evaluating RAF/MEK inhibitor VS-6766, combined with FAK inhibitor defactinib, in patients with low-grade serous ovarian cancer (LGSOC). T...
Preliminary Data on VS-6766 and Defactinib Combination Continues to Show Encouraging Response Rates, Durability and a Favorable Safety Profile in KRAS Mutant Low-Grade Serous Ovarian Cancer in Investigator-Initiated Trial New Preclinical Data Demonstrating Synergy and Tumor Regression ...
Verastem Oncology (NASDAQ: VSTM ) +5% premarket will host an investor conference call to discuss the updated clinical data from the low-grade serous ovarian cancer (LGSOC) cohort of the ongoing investigator-initiated Phase 1/2 FRAME study. More news on: Verastem, Inc., Heal...
New Results Evaluating Combination of VS-6766 and Defactinib to be Presented at the 2 nd Annual RAS-Targeted Drug Development Summit Management to Host Investor Conference Call and Webcast on Wednesday, September 16 at 8:00 AM ET Verastem, Inc. (Nasdaq:VSTM) (also known as Verast...
Are These WeBull & Robinhood Penny Stocks On Your List This Week? Whether you’re looking for penny stocks to buy on Robinhood, WeBull, or other brokers, it’s good to have a strategy in place, first. One of the quickest ways to cut through the noise is to find companies with...
"The books that the world calls immoral are books that show the world its own shame. ” ― Oscar Wilde, The Picture of Dorian Gray Today, we revisit Verastem ( VSTM ), a small oncology outfit that comes up in comments from time to time. In early August, the company announce...
Shares of Verastem (NASDAQ: VSTM) jumped by as much as 11% this morning after the company reported second-quarter earnings and announced a deal to sell development rights to a drug. The stock gave up those gains and closed breakeven for the day. Revenue in the second quarter was $4.3 millio...
Following through on its previously announced decision to sharpen its strategic focus on RAF/MEK inhibitor VS-6766 and it FAK inhibitor program in KRAS mutation-positive solid tumors, Verastem (NASDAQ: VSTM ) has sold global development and commercialization rights to Copiktra (duvelisib...
Announced Path Forward for VS-6766 and Defactinib Combination Following Meeting with FDA Phase 2 Registration-Directed Trials Expected to Commence by Year End 2020 in Both Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer Company Monetizes COPIKTRA ® ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...